The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
December 23rd 2024
Exercise interventions may help manage chemotherapy-induced peripheral neuropathy (CIPN) in patients with ovarian cancer through improved physical activity and muscle function, but evidence remains limited.
What We're Reading: Valeant Increases Aid-in-Dying Drug Price Ahead of California's New Law
March 24th 2016What we're reading, March 24, 2016: Valeant doubles the price of aid-in-dying drug; the Supreme Court seems split on contraception case; and less than 3% of Americans meet qualifications for a healthy lifestyle.
Read More
ACS Now Has a Guideline for Care of Head and Neck Cancer Survivors
March 23rd 2016With an increasing population of head and neck cancer survivors in the United States, the American Cancer Society identified the need to develop survivorship guidelines that can lend support to primary care clinicians and other health practitioners as they care for survivors.
Read More
Duke Study Recommends Against Annual LDCT in a Subset of High-Risk Lung Cancer Patients
March 22nd 2016"Our analysis suggests that annual screens may not be warranted for patients who have had an initial negative scan, and future risk prediction and cost-effectiveness models could incorporate these data to improve screening guidelines," said the study's lead author.
Read More
Increased Travel Burden Could Reduce Prospect of Radiation Treatment
March 21st 2016Analysis of data on nearly 27,000 patients with rectal cancer found distance from site of radiation therapy, along with a few other factors, could significantly impact the possibility of the patient receiving treatment.
Read More
NICE Reverses Stand on Abiraterone After Janssen Submits Additional Data
March 21st 2016Based on the review of additional data submitted by Janssen, an appraisal committee from the National Institute for Health and Care Excellence (NICE) has finalized a guidance that recommends abiraterone for use in some prostate cancer patients prior to chemotherapy.
Read More